Oppenheimer reiterated coverage on Veru with a new price target
$VERU
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer reiterated coverage of Veru with a rating of and set a new price target of $24.00 from $19.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $5.00 | Buy | B. Riley Securities |
| 3/28/2024 | $3.00 | Outperform | Raymond James |
| 6/7/2023 | $1.00 | Underperform → Hold | Jefferies |
8-K - VERU INC. (0000863894) (Filer)
8-K - VERU INC. (0000863894) (Filer)
10-Q - VERU INC. (0000863894) (Filer)
Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced a successful meeting with FDA providing regulatory clarity for enobosarm, a selective androgen receptor modulator, as a muscle preservation drug product candidate in combination with GLP-1 RA for greater weight loss for the treatment of obesity. Highlights from FDA meeting The regulatory landscape continues to evolve for muscle preservation drugs in the treatment of obesity. Based on FDA feedback on Veru's clinical development program for enobosarm,
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation-- --Company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study-- --Company anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserv
Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ:VERU), a late clinical-stage biopharmaceutical company advancing treatments for cardiometabolic and inflammatory diseases, has selected a novel modified-release oral formulation of enobosarm that will utilize Laxxon's proprietary SPID® (Screen Printing Innovation Drug)-Technology. The novel tablet formulation achieved the desired target release profile, including a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a si
4 - VERU INC. (0000863894) (Issuer)
4 - VERU INC. (0000863894) (Issuer)
4 - VERU INC. (0000863894) (Issuer)
4 - VERU INC. (0000863894) (Issuer)
4 - VERU INC. (0000863894) (Issuer)
4 - VERU INC. (0000863894) (Issuer)
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation-- --Company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study-- --Company anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserv
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Tuesday, August 12, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 third quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for
MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan
SC 13G/A - VERU INC. (0000863894) (Subject)
SC 13G/A - VERU INC. (0000863894) (Subject)
SC 13G - VERU INC. (0000863894) (Subject)
B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00
Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00
Jefferies upgraded Veru from Underperform to Hold and set a new price target of $1.00